Heparin-induced thrombocytopenia: Minimising the risks in the elderly patient

Drugs and Aging

Volumn 16, Issue 5, 2000, Pages 351-364

  Tardy Poncet, Brigitte ^a,b   Tardy, Bernard ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; DANAPAROID; DESULFATOHIRUDIN; FIBRINOLYTIC AGENT; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NEOTHROMBIN; PROTAMINE SULFATE; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR; WARFARIN;

AGED; BLEEDING; CLINICAL TRIAL; DIAGNOSTIC ERROR; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; EARLY DIAGNOSIS; GANGRENE; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; THROMBECTOMY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

EID: 0034117522     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016050-00005     Document Type: Review

References (82)

1. 1. Boon DMS, Kappers-Klunne MC, Michiels JJ, et al. Heparin-induced thrombocytopenia and thrombosis: a potential fatal complication in a routine treatment. Neth J Med 1995; 46: 146-52
2. 2. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-7
3. 3. Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997; 56: 12-6
4. 4. Magnani HN. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia: proceedings of a workshop held in London, 1996 Nov 1. Platelets 1997; 8 (1): 74-81
5. 5. Tardy-Poncet B, Tardy B, Reynaud J, et al. Efficacy and safety of Orgaran (ORG 10172) in critically ill patients with heparin associated thrombocytopenia. Chest 1999; 115: 1616-20
6. 6. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-30
7. 7. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annu Rev Med 1989; 40: 31-44
8. 8. Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8
9. 9. Greinacher A, Potzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-51
10. 10. Amiral J, Wolf M, Fischer AM, et al. Pathogenicity of IgA and/or IgM antibodies to heparin-Pf4 complexes in patients with heparin-induced thrombocytopenia [letter]. Br J Haematol 1996; 92: 954
11. 11. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Thromb Haemost 1995; 21: 106-16
12. 12. Warkentin TE, Hayward CPM, Bochkov LK. Sera from patients with heparin-induced thrombocytopenia generate platelet derived microparticles with pro-coagulant activity an explanation for the thrombolic complications of heparin-induced thrombocytopenia [abstract]. Blood 1994; 84: 3691
13. 13. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated-thrombocytopenia. N Engl J Med 1987; 316: 581-9
14. 14. Zalcberg JR, McGrath K, Dauer R, et al. Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation. Br J Haematol 1983; 54: 955-60
15. 15. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991; 10: 1-34
16. 16. Tardy-Poncet B, Tardy B, Grelac F, et al. Pentosan polysulphate-induced thrombocytopenia and thrombosis. Am J Hematol 1994; 45: 252-7
17. 17. Tardy B, Tardy-Poncet B, Zeni F, et al. Thrombocytopenia associated with low molecular weight heparin [letter]. Lancet 1991; 338: 1217
18. 18. Doty JR, Alving BM, Mc Donnell DE, et al. Heparin-associated thrombocytopenia in the neurosurgical patient. Neurosurgery 1986; 19: 69-72
19. 19. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-9
20. 20. Hirsch J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetic, dosing considerations, monitoring, efficacy and safety. Chest 1995; 108 Suppl.: 258-75S
21. 21. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5
22. 22. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 629-35
23. 23. Boskhov LK, Warkentin TE, Hayward CPM, et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322-8
24. 24. Belmain J, Trivalle C, Medjahed S, et al. Use of low molecular weight heparin in geriatric hospitals and institutions in France: a national one-day survey in 97 centers [abstract]. Haemostasis 1998; S2: 297
25. 25. Gallus AS, Jackaman J, Tillett J, et al. Safety and efficiency of warfarin started early after submissive venous thrombosis or pulmonary embolism. Lancet 1986; II: 1293-6
26. 26. Chong BH. Heparin-induced thrombocytopenia. Aust N Z J Med 1992; 22: 145-52
27. 27. Erni J, Frey HR, Locher G. The heparin-induced thrombosis-thrombocytopenia syndrome. Dtsch Med Wochenschr 1987; 112: 801-5
28. 28. Ansell J, Deykin D. Heparin-induced thrombocytopenia and recurrent thromboembolism. Am J Hematol 1980; 8: 325-2
29. 29. Hach-Wunderle V, Kainer K, Krug B. Heparin-associated thrombosis despite normal platelet counts. Lancet 1994; 344: 469-70
30. 30. Leroy J, Leclerc MH, Delahousse B. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216). Semin Thromb Haemost 1985; 11: 326-9
31. 31. Buge A, Poisson M, Vidhaillet M, et al. Thrombopenia and disseminated intravascular coagulation during treatment with heparin: two cases with neurological complications. Rev Neurol 1988; 144: 289-94
32. 32. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92: 494-7
33. 33. Warkentin TE. Heparin-induced thrombocytopenia, heparin-induced skin lesions, and arterial thrombosis [abstract]. Thromb Haemost 1997; Suppl.: 562
34. 34. Silver D, Kapsch D, Tsoi E. Heparin-induced thrombocytopenia, thrombosis and hemorrahge. Ann Surg 1983; 198: 301-6
35. 35. Laster J, Cikrit D, Walker N, et al. The heparin-induced thrombocytopenia syndome: an update. Surgery 1987; 102: 763-8
36. 36. Greinacher A, Amiral J, Dummel V. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin induced platelet activation test and platelet factor 4/heparin enzyme linked immunosorbent assay. Transfusion 1994; 34: 381-5
37. 37. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30
38. 38. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344-50
39. 39. Brandt J, Isenhart CE, Osborne JM. On the role of platelet FCγ IIA phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74: 1564-72
40. 40. Lecompte T. Drug-dependent platelet activating IgG: heparin and streptokinase. In: Seghatchian MJ, Samama MM, Hecker SP, editors. Hypercoagulable states. New York (NY): CRC Press, 1996: 173-8
41. 41. Isenhart CE, Brandt JT. Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1993; 99: 324-30
42. 42. Salem HH, van der Weyden MB. Heparin-induced thrombocytopenia: variable platelet rich plasma reactivity to heparin dependent aggregating factor. Pathology 1983; 15: 297-9
43. 43. Greinacher A, Michels I, Liebenhoff U, et al. Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol 1993; 84: 711-6
44. 44. Salzman EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
45. 45. Greinacher A, Michels I, Kiefel V. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-6
46. 46. Amiral J, Bridey F, Dreyfus M. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6
47. 47. Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/ heparin ELISA with the 14C serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995; 104: 648-54
48. 48. Amiral J, Marfaing-Koka A, Wolf M. Presence of auto-antibodies to interleukin 8 or neutrophil activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996; 88: 410-6
49. 49. Amiral J. Diagnostic tests in heparin-induced thombocytopenia: proceedings of a workshop held in London on 1 November 1996. Heparin-induced thrombocytopenia: an under-diagnosed syndrome? Platelets 1997; 8: 65-82
50. 50. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S-510S
51. 51. Tardy B, Tardy-Poncet B, Fournel P, et al. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost 1999; 82: 1199-200
52. 52. Tardy-Poncet B, Mahul P, Beraud AM, et al. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome. Br J Haematol 1995; 90: 969-70
53. 53. Tardy B, Tardy-Poncet B, Viallon A. Fatal danaparoid sodium-induced thrombocytopenia and thromboses [letter]. Thromb Haemost 1998; 80: 530
54. 54. Meuleman DG. Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 1992; 22: 58-65
55. 55. ten Cate H, Henny CP, ten Cate JW, et al. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients. Thromb Res 1985; 38: 211-22
56. 56. ten Cate H, Lamping RJ, Henny CP, et al. Automated amidolytic method for determining heparin, a heparinoid and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem 1984; 30 (6): 860-4
57. 57. Bradbrook ID, Magnani HN, Moelker HC, et al. Org 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol 1987; 23: 667-75
58. 58. Henny CP, ten Cate H, ten Cate JW, et al. Thrombosis prophylaxis in an ATHI deficient pregnant woman: application of a low molecular weight heparinoid [letter]. Thromb Haemost 1986; 55: 301
59. 59. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70: 554-61
60. 60. Greinacher A, Eckhardt T, Mussmann J. Pregnancy complicated by heparin-associated thrombocytopenia: management by prospectively in vitro selected heparinoid (Org 10172). Thromb Res 1993; 71: 123-6
61. 61. Mikhailidis DP, Barradas MA, Mikhailidis AM, et al. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol 1984; 17: 43-8
62. 62. Mikhailidis DP, Fonseca VA, Barradas MA, et al. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172). Br J Clin Pharmacol 1987; 24: 415-24
63. 63. Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992; 22: 85-91
64. 64. Ramakrishna R, Manoharan A, Kwan YL. Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin), and heparinoid, danaparoid (Orgaran). Br J Haematol 1995; 91: 736-8
65. 65. Wilde MI, Markham A. Danaparoid: a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 6: 903-24
66. 66. Chong BH, Ismail F, Cade J. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73: 1592-6
67. 67. Rowlings PA, Mansberg R, Rozenberg MC, et al. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin-dependent thrombocytopenia and thrombosis. Aust NZ J Med 1991; 21: 52-4
68. 68. Tardy-Poncet B. French experience in the use of Orgaran as an alternative antithrombotic treatment for patients with heparin-induced thrombocytopenia [abstract]. Thromb Haemost 1997; Suppl.: 1825
69. 69. Greinacher A, Vôlpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80
70. 70. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100: 587-93
71. 71. Eichler P, Greinacher A. Anti-hirudin antibodies induced by recombinand hirudin in the treatment of patients with heparin-induced thrombocytopenia [abstract]. Ann Hematol 1996; 72 Suppl.: A4
72. 72. Schwarz RP. Update on the clinical development of Novastan (Argatroban): a small-molecule direct thrombin inhibitor. In: Zavoico G, editor. Advances in anticoagulant and antithrombotic drugs, IBC Biomedical Library Series. Southborough (MA): International Business Communication Inc., 1996
73. 73. Lewis BE, Walenga JM, Wallis DW. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997; 23: 197-202
74. 74. Weitz JL, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91
75. 75. Willerson JT, Casscells W. Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal? J Am Coll Cardiol 1993; 21: 1048-51
76. 76. Wallis DE, Lewis BE, Messmore H. Heparin-induced thrombocytopenia and thrombosis syndrome. Clin Appl Thromb Hemost 1998; 4: 160-3
77. 77. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-12
78. 78. Cairns JA, Kennedy JW, Fuster V. Coronary thrombolysis. Chest 1998; 114: 634-57S
79. 79. Meneveau N, Bassand JP, Schiele F, et al. Safety of thrombolytic therapy in the elderly patients with massive embolism: a comparison with non-elderly patients. J Am Coll Cardiol 1993; 22: 1075-9
80. 80. Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated factors. Chest 1997; 111: 1241-5
81. 81. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena cava fillers in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis. N Engl J Med 1998; 338: 409-15
82. 82. Sobel M, Adelman B, Szentpetery S, et al. Surgical management of heparin-associated thrombocytopenia: strategies in the treatment of venous and arterial thromboembolism. J Vasc Surg 1988; 8: 395-401